Entities / Company
Iovance Biotherapeutics.
American biopharmaceutical startup
- Reports this week
- 1
- Active events
- 1
- Connections
- 57
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
One to three months ago
-
Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.Well supported5 reports
-
Investors are weighing risk and valuation factors for stocks traded on the Nasdaq electronic stock exchange.Some support1 report
-
Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.Well supported6 reports3 developments inside
-
Chardan Capital downgraded its price objective for Iovance Biotherapeutics, which trades on the Nasdaq stock exchange.Some support1 report
-
Iovance Biotherapeutics stock traded on Nasdaq and was compared to Nvidia's past growth.Some support1 report
Gone quiet
No new reports in 90+ days-
Tariffs and onshoring trends are benefiting AI stocks, while a company acquisition enhances its liver disease portfolio, aided by a breakthrough designation.Some support7 reports4 developments inside
-
Iovance Biotherapeutics maintains license agreements with Cellectis SA, and both companies also have license agreements with Novartis.Some support1 report
-
Iovance Biotherapeutics secured conditional approval for its drug Amtagvi in Australia, marking an expansion into high prevalence markets.Some support1 report
-
Iovance Biotherapeutics filed a disclosure with the SEC detailing stock activity.Some support1 report
-
Iovance Biotherapeutics received conditional approval from Health Canada for its drug Amtagvi.Well supported3 reports
-
Roche was appointed as the new CFO of Iovance Biotherapeutics.Some support2 reports
-
Iovance Biotherapeutics is benefiting from potential Trump-era tariffs, leading to Wells Fargo lowering its price target despite strong sales.Some support1 report
-
Iovance Biotherapeutics saw revenue gains from its product lifileucel (Amtagvi), but the company faced market underperformance and corporate leadership changes.Some support4 reports1 development inside
-
Goldman Sachs supported a 'Buy' rating for Iovance Biotherapeutics based on positive Amtagvi data.Speculative1 report
-
Iovance Biotherapeutics appointed Marc R Theoret as SVP Regulatory Strategy on July 11, 2025.Some support1 report
-
Yahoo! Finance provided average price target data for Iovance Biotherapeutics on July 21, 2025.Some support1 report
-
The FDA approved Amtagvi, a T cell therapy developed by Iovance Biotherapeutics.Well supported8 reports
-
TIL therapy was traced back to research conducted by the National Institutes of Health.Some support1 report
-
Shopify and Iovance Biotherapeutics were noted as promising stocks in August 2025.Some support1 report
-
Iovance Biotherapeutics received FDA approval for a cancer drug, with its stock performance contrasting against the S&P 500 slide.Some support1 report
-
Operational challenges led to Artisan Small Cap Fund exiting its stake in Iovance Biotherapeutics.Some support1 report
-
Iovance Biotherapeutics is evaluating its drug Amtagvi with Merck's Keytruda, potentially leading to FDA label expansion.Well supported6 reports
-
Iovance Biotherapeutics drafted Jefferies Financial Group to be its sales agency.Some support1 report
-
Iovance Biotherapeutics received conditional approval for its drug lifileucel, expanding its potential market reach.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Iovance Biotherapeutics this week
News at the entities that move Iovance Biotherapeutics most-
Nasdaq StructuralIREN has listed on the Nasdaq stock exchange and secured a license for an AI campus to serve European customers.Moves Iovance Biotherapeutics
-
FDA StructuralThe FDA cited Procter & Gamble for deviations from CGMP regulations related to the manufacturing of Crest children's toothpaste.Moves Iovance Biotherapeutics
-
TD Cowen Mentioned togetherTD Cowen raised its price target for Celcuity Inc., which saw a stock price increase driven by a bullish rating.Moves Iovance Biotherapeutics
-
UBS OperationalCLSA retained an 'outperform' rating on M&M, and UBS acquired a stake in an Indian company.Moves Iovance Biotherapeutics
-
MarketBeat Mentioned togetherMarketBeat identifies Celsius Network as a stock to watch, noting that the company sells products across multiple continents, including Europe.Moves Iovance Biotherapeutics
-
Citigroup Mentioned togetherCitigroup reaffirmed its market outperform rating for Pitney Bowes.Moves Iovance Biotherapeutics
Connections
The 17 strongest of 57, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Nasdaq Structural
Iovance Biotherapeutics is formally listed and trades on the Nasdaq stock exchange.
-
FDA Structural
The FDA formally regulates and grants market approval to Iovance Biotherapeutics' therapeutic products.
-
lifileucel Structural
Iovance Biotherapeutics develops and delivers the lifileucel therapy, whose sales and approval drive the company's revenue and market reach.
-
SEC Structural
Iovance operates as a company under the regulatory purview of the U.S. Securities and Exchange Commission (SEC).
-
TD Cowen Mentioned together
TD Cowen issued positive financial ratings and target price increases for Iovance Biotherapeutics shares.
-
UBS Operational
UBS actively tracks and influences Iovance's market valuation through analyst recommendations and coverage.
-
Editas Medicine Operational
The two companies are viewed as competitors in the market, facing joint evaluation from investors based on risk and valuation.
-
MarketBeat Mentioned together
MarketBeat provides stock ratings and analyst coverage for Iovance Biotherapeutics.
Show all 17 connections
-
Celldex Therapeutics Operational
The evidence places both companies as competitors operating within the mid-cap healthcare market segment.
-
Therapeutic Goods Administration Structural
TGA granted conditional approval for Iovance Biotherapeutics' product, Amtagvi.
-
Citigroup Mentioned together
Citigroup provided and reiterated an 'outperform' rating on Iovance Biotherapeutics shares.
-
Moderna Mentioned together
Both companies are categorized as leading players within the biotechnology sector.
-
Yahoo! Finance Mentioned together
Yahoo! Finance provides financial data and consensus analyst estimates for Iovance Biotherapeutics.
-
Barclays Mentioned together
Barclays provided a target price and rating change for Iovance Biotherapeutics.
-
Medicare Shared context
Iovance Biotherapeutics operates within the context of Medicare payer policies.
-
Philadelphia Shared context
The company operates from its Cell Therapy Center located within the boundaries of Philadelphia.
-
Nvidia Mentioned together
The relationship is based on a single historical comparison noting that Iovance was compared to Nvidia's past growth trajectory.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
1 eventAugust 2026
3 events- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.
- Chardan Capital downgraded its price objective for Iovance Biotherapeutics, which trades on the Nasdaq stock exchange.
- Iovance Biotherapeutics stock traded on Nasdaq and was compared to Nvidia's past growth.
Show 2 earlier months
July 2026
1 eventJune 2026
19 events- Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.
- Tariffs and onshoring trends are benefiting AI stocks, while a company acquisition enhances its liver disease portfolio, aided by a breakthrough designation.
- Iovance Biotherapeutics secured conditional approval for its drug Amtagvi in Australia, marking an expansion into high prevalence markets.
- Iovance Biotherapeutics filed a disclosure with the SEC detailing stock activity.
- Iovance Biotherapeutics received conditional approval from Health Canada for its drug Amtagvi.
- Roche was appointed as the new CFO of Iovance Biotherapeutics.
- Iovance Biotherapeutics is benefiting from potential Trump-era tariffs, leading to Wells Fargo lowering its price target despite strong sales.
- Iovance Biotherapeutics saw revenue gains from its product lifileucel (Amtagvi), but the company faced market underperformance and corporate leadership changes.
- Goldman Sachs supported a 'Buy' rating for Iovance Biotherapeutics based on positive Amtagvi data.
- Iovance Biotherapeutics appointed Marc R Theoret as SVP Regulatory Strategy on July 11, 2025.
- Yahoo! Finance provided average price target data for Iovance Biotherapeutics on July 21, 2025.
- The FDA approved Amtagvi, a T cell therapy developed by Iovance Biotherapeutics.
- TIL therapy was traced back to research conducted by the National Institutes of Health.
- Shopify and Iovance Biotherapeutics were noted as promising stocks in August 2025.
- Iovance Biotherapeutics received FDA approval for a cancer drug, with its stock performance contrasting against the S&P 500 slide.
- Operational challenges led to Artisan Small Cap Fund exiting its stake in Iovance Biotherapeutics.
- Iovance Biotherapeutics is evaluating its drug Amtagvi with Merck's Keytruda, potentially leading to FDA label expansion.
- Iovance Biotherapeutics drafted Jefferies Financial Group to be its sales agency.
- Iovance Biotherapeutics received conditional approval for its drug lifileucel, expanding its potential market reach.